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2.21.9 mmHg pre-procedural to 3.61.7 mmHg at follow up in rest (p0.02) and to
6.22.7 mmHg (p0.001) during exercise. The maximum MVPG also significantly
increased from 6.13.4 mmHg pre-procedural to 9.93.3 mmHg at follow up in rest
(p0.002) and during exercise to 13.74.6 mmHg (p 0.003). Heart rate en systolic
blood pressure increased both significantly during exercise.
Conclusions: MitraClip implantation results in an expected increase of transmitral
pressure gradient during exercise, however with no evidence of clinically significant
mitral stenosis.
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Background: Purpose of the study is to characterize high-risk patients with mitral
regurgitation (MR) treated with the MitraClip device (Abbott Vascular, Abbott Park,
Illinois) and to assess the impact of preoperative TR3	 on the outcomes at mid-term
follow-up after MitraClip treatment.
Methods: From November 2008 to March 2012, 106 consecutive patients with
degenerative and functional moderate to severe or severe MR underwent MitraClip
implantation at our institution. All the patients were assessed by a preoperative standard-
ized protocol, which included TEE , angiography and evaluation of the surgical risk. The
functional status was assessed by 6MWT, while quality of life was evaluated by MLHFQ
and SF-36 questionnaires. Short and mid-term outcomes of patients with and without
concomitant TR3	 (TR group and no-TR group, respectively) were compared.
Results: Preoperative TR3	 was present in 21/106 patients (19.8%). Patients of the 2
groups were similar for age, comorbidities and surgical risk. Functional etiology was
present in 71.4% of the TR group and in 70.6% of the no-TR group (p0.9). Preoperative
echocardiography showed similar LVEDD (p0.5) and LVEF (p0.4). Patients of the
TR group had worse quality of life (MLHFQ 44.7 Vs 36.9- p0.04; SF-36 physical
domain 30.4 Vs 36.6 –p0.004). In-hospital mortality was 0% in TR group and 1.2% in
no-TR group (p0.6). Similar reduction of MR to 2	 before discharge was achieved
in the 2 groups (TR group90.5%, no-TR group91.6%, p 0.8). At 1 year follow-up,
actuarial survival was 79.410.6% for TR group and 91.13.9% for no-TR group
(p0.5) while freedom from MR3	 was 67.712.1% for TR group and 85.15.1%
for no-TR group (p0.04). At last follow-up (mean 9.2 months, range 1-41 months),
overall freedom from death, MR3	 and rehospitalization for HF was 47.6% for TR
group and 69% for no-TR group (p0.06). The presence of preoperative TR3	 was
identified as predictor of recurrence of MR3	 (OR 3.75).
Conclusions: TR is associated with more impaired QoL in MitraClip candidates.
Moreover, in patients with significant TR, the recurrence of MR3	 and the incidence
of death, MR recurrence and rehospitalization for HF result higher at mid-term follow-up.
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Background: Percutaneous closure of mitral valve periprosthetic leak (MPL) is being
sought as an alternative to repeated surgery. Different device have been used to
percutaneous repair. Objective: Describe our population undergoing percutaneous closure
with Amplatzer Vascular Plug III® (AVPIII), and assess clinical events.
Methods: Prospective registry of all patients (p) were treated percutaneously for at least
1 MPL. AVPIII device used. Procedural success: device was implanted and the MPL
regurgitation decreased. Device failure: death or new intervention on the same MPL at 30
days.
Results: Fifty four p, age 6712years. 94% with mechanical mitral valve; number of
surgery on the mitral valve 2.10.9. Time from last surgery to percutaneous intervention
9.87.8years. Clinical heart failure 89.2% and hemolytic anemia 88,4% was indication.
NYHA functional class 3,30,6, hematocrit 28,74,8%, and MPL regurgitation grade
3,20,8. Euroscore log 19.313.2. 59 MPL initially were attempted to close in 63
procedures. A 2° procedure was done 9 MPL and 3° attemp in 1 MPL, with AVPIII
implant success in 96,2% of p. 3p simultaneous closure of MPL and aortic leak were done.
Seventy AVPIII were initially implanted in 52p. MPL regurgitation decreased
grade1,30,7.Complications of procedure: embolization 1p(captured and implanted in
the same procedure), impingement mitral prosthetic disc 4p(emergency surgery 2p) and
permanent pacemaker 1p. Procedure success 92.5%p. Clinical events at 30 days:
Percutaneous reintervention residual regurgitation 3p, mitral valve surgery 1p, stroke 1p,
hospitalization for heart failure 6p and death 2p. Clinical success in 85.1%p. Follow-up.
Improvement NYHA functional class in at least 1 grade occurred in 80% (p0.03).
NYHA fuctional class 2,530,9(p0,03), hematocrit 34,15%(p0,01), and MPL
regurgitation 2,21,3 (p0,04).
Conclusions: Percutaneous repair of MPL is a feasible alternative with a high immediate
technical success rate, and few complications. At follow up, recovery of both functional
class, hematocrit and decrease of at least 1 degree regurgitation was observed. Patients can
undergo reintervention for residual or new leak.
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Background: Suboptimal result of the MitraClip procedure (Abbott Vascular, Santa
Clara, California) might be related to inadequate number of clips. In some cases of the
MitraClip procedure, 2nd clip is required to be placed for residual mitral regurgitation
(MR) after 1st clip placement. However the reports of the 2nd clip placement outcome are
sparse.
Methods: We retrospectively investigated 70 out of 148 MitraClip procedures (47.3 %)
that required 2nd clip placement (46 men, mean age 72.1 13.1 years, 40 functional MR
cases). Procedural success was defined as MR severity2	 after clip placement. The 1st
clip time is defined as the time from 1st clip delivery system (CDS) insertion until 1st clip
placement. And 2nd clip time is defined as the time from 2nd CDS insertion until 2nd clip
placement.
Results: Procedural success was achieved in 67 of 70 cases (95.7%). In failed 3 cases, the
procedure was aborted for the following reason: increased trans mitral gradient with 2nd
clip, inadequate MR reduction and failure of leaflet insertion (2nd clip wasn’t released in
all 3 cases). There were no complications related to 2nd clip placement (clip detachment,
worsening MR, significant mitral stenosis and non-elective cardiac surgery for adverse
events). 2nd clip time was significantly shorter than 1st clip time [42.8 22.3 vs. 71.5
42.1 min, p  0.001]. And there was no significant difference in 2nd clip time between
functional and degenerative etiologies [40.3  25.4 vs. 46.0  17.9 min, p  0.3,
respectively].
Conclusions: 2nd clip placement further improves MR reduction, and placement time is
shorter than 1st clip placement time, without increasing risk.
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Background: Acute hemodynamic changes from the MitraClip (Abbott Vascular, Santa
Clara, CA) procedure have been shown for mitral regurgitation (MR) from mixed etiology, but
have not been elucidated in functional MR alone. Also, there is a misconception that reducing
functional MR may lead to a detrimental change in acute hemodynamics.
Methods: A retrospective review was performed on 85 consecutive patients with
functional MR (mean age 7611 years, 30 (35%) females) who had full set of
hemodynamics prior to and after the MitraClip procedure. 57 (67%) patients were
included in the high-risk registry (mean STS score 14.97.4%) with 78 (92%) in NYHA
functional class III or IV and 77 (91%) with MR grade 4	. There were 34 (40%) patients
with left ventricular ejection fraction (LVEF)  35% (mean 266%); overall mean left
ventricular end systolic diameter of 4010mm.
Results: There were significant improvements in the cardiac index (CI; mean pre CI of
1.920.47 L/min/m2 vs. post CI 2.430.61 L/min/m2, p0.001) and mean left atrial
pressures (MLAP; mean pre MLAP of 20.76.7 mmHg vs. post MLAP 17.25.7
mmHg, p0.001). Improvements in CI and MLAP was observed in 75/85 (88%) and
50/74 (68%) patients respectively. At a mean follow-up of 139months, 76/85 (89%)
was in NYHA functional class I or II (from 78/85 (92%) in NYHA class III or IV at
baseline, p0.001) and 71/85 (84%) had MR grade  2	 (from 85/85 (100%) in MR
grade 3	 or 4	 at baseline, p0.001).
Conclusions: In patients with functional MR, the MitraClip procedure resulted in a
significant change in CI and MLAP.
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Background: Transcatheter mitral valve-in-valve / valve-in-ring implantation is an
emerging therapeutic alternative for patients with failed mitral valves after surgical
intervention and may obviate the need for a redo operation. We aimed to evaluate the
clinical results of this technique using a large worldwide registry.
Methods: The registry included 70 patients with degenerated mitral valves after surgical
intervention (11.4% ring only, median of 9 years post procedure) from 17 centers. Mean
age 74.0 11.3 years; 70% female (STS score 16.2 10.4%). The mode of failure was
regurgitation (n36, 51.4%), stenosis (n13, 18.6%), and combined stenosis and
regurgitation (n21, 30%).
Results: Transcatheter Edwards SAPIEN (Edwards Lifesciences, Irvine, CA) implanta-
tion was performed in all cases (23 mm in 22.9%, 26 mm in 58.6%, and 29 mm in 18.6%).
Procedural access was transapical in 60 cases (85.7%); transseptal in 7 (10%), and through
the left atrium via right mini-thoracotomy in 3 (4.3%). Combined procedures included 3
aortic valve-in-valves, transapical aortic valve replacement, tricuspid valve-in-ring im-
plantation, and transapical paravalvular leak closure. Device malposition appeared in
4.3% of cases and post implantation valvuloplasty was utilized in 12.1%. Post-procedure,
mitral valve area was 2.1  0.6 cm2, valve maximum / mean gradients were 13.6  6.4
mmHg / 6.4 2.7, respectively, and significant mitral regurgitation (	2) was observed
in 5.7% of patients. Median length of hospital stay was 7 days. At 30-day follow-up,
all-cause mortality was 10.3% and 82.3% were at New York Heart Association functional
class I/II.
Conclusions: Mitral valve-in-valve/ valve-in-ring implantations, performed in very
high-risk patients, were clinically effective in most patients with degenerative mitral
valves after surgery. The safety and efficacy of this approach should be further examined.
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Background: 3C-HF has been recently proposed as a simple score for prediction of heart
failure all-cause 1 year mortality, on the basis of patient cardiac and comorbid condition.
We evaluated his role in outcome prediction after MitraClip procedure.
Methods: From October 2008, 120 consecutive patients underwent MitraClip implan-
tation at our Institution. At time of study 76 patients have reached 1-year follow-up. We
retrospectively analysed in-hospital and 1-year outcome association with pre-operative
3C-HF.
Results: Pre-operative calculated 1-year expected mortality was 35.5%; which was
significantly different for FMR and DMR: 43% vs 23.5% (p0.0018). Overall 30 days
mortality was 1.3% (0.0% and 4.2% in FMR and DMR, respectively; p0.13). Higher
3C-HF score was not predictor of 30d mortality (p0,36). Higher 3C-HF score was
otherwise significantly related to post-operative need of hemotransfusion (p0.0009),
ultrafiltration (p0.007), cardiogenic shock (p0.01), liver failure (p0.04), new renal
failure (p0.003), longer length of stay (p0.01) and need to discharge to rehabilitation
(p0.001). Overall observed mortality at 1-year was 10.5%, which represents a threefold
reduction compared to the predicted mortality by 3C-HF. Higher 3C-HF values were
associated to higher 1-year mortality (p0.03). One year mortality was 11.5% and 8.3%
for FMR and DMR, respectively (p0.66). ROC curve analyses showed a predictive
cut-off level of 3C-HF of 58% (AUC 0.68, p0.07). At 1 year higher 3C-HF was also
associated to need of re-hospitalization for heart failure (p0.004) and worse NYHA
class (p0.01). Preprocedural 3C-HF was 51.425.6 in patients who had at least one
hospitalization within one year from the index procedure, vs 33.721.1 in those who did
not require hospitalization. QoL tended to be better in patients with lower 3C-HF
(p0.18).
Conclusions: 3C-HF predicts 1-year mortality and symptomatic outcome after Mitra-
Clip; moreover it is associated to acute post-operatve complications. Observed mortality
in patients undergoing MitraClip implantation was three times lower than the expected
one year mortality as predicted by the 3C-HF score, suggesting a prognostic benefit of
transcatheter mitral repair in hea.
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Background: The value of anatomical and functional selection criteria for MitraClip
(Abbott Vascular Inc, Menlo Park, California) still has to be validated in the daily clinical
practice.
Methods: Since October 2008, 120 patients underwent MitraClip at our institution. At
time of the study, 76 patients reached 1 year follow-up (68.4% FMR, 31.6% DMR).
Mitral anatomy was defined “unfavorable” (U-FA) in case of: non-central jet, coaptation
depth(CD)10mm, coaptation lengh(CL)2mm, flail gap(FG)10mm, flail width
(FW)15mm, valve area(VA)4cm2, multiple jets, severe annular calcification, signif-
icant leaflet cleft/perforation, target leaflet calcification, leaflet retraction.
Results: U-FA anatomy was found in 46 patients (63.1%), more frequently in FMR
(78.8%) rather than DMR (29.1%); the most common reason for U-FA anatomy was CD
in 86.9% of patients. Among pre-operative features, U-FA patients had larger EDD (68.6
vs. 64.0mm, p0.04) and lower EF (32.3 vs. 46.2%, p0.0007). MitraClip implantation
was successful in 97.4% of patients; conversion to mitral valve replacement was required
in 2 patients (one from each group). Successful reduction of MR (post-operative MR2)
was achieved in 87.5% vs 92.8% (p0.46), procedural time was 106 vs 115 minutes
(p0.4) and post-operative length of stay was 8.5 vs 6.5 days (p0.55), for U-FA and
favorable (FA), respectively. At 1-year, actual survival was 91.6% vs 85.7% (p0.41),
the frequency of patients with MR2 was 76.7% and 75% (p0.87) and NYHAII was
88.4% vs 91.7% (p0.67) for U-FA and FA, respectively. Three partial clip detachments
occurred in the DMR patients (1 in U-FA, 2 in FA, p0.25) and none in FMR patients.
Analyses of single selection criteria showed no significant association with 1-year rates of
MR2, mortality or clip detachment. All analyses conducted separately in FMR and
DMR strati did not give significantly different results.
Conclusions: MitraClip implantation is feasible and effective in patients regardless of the
suggested anatomical selection criteria. Presence of unfavorable anatomy by means of
EVEREST criteria did not correlate with 1-year outcomes, both in functional and
degenerative settings.
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